Loading...
Market
What will be the changes in cardiovascular health metrics among Ozempic users in China by end of 2024?
2
Resolution / Starting Odds
Significant improvement • 25%
Moderate improvement • 25%
No change • 25%
Worsening • 25%
Health reports and studies from Chinese medical institutions and health organizations
Story
China Adopts Ozempic in Weight Loss Guidelines, British Heart Foundation Optimistic
Sep 3, 2024, 06:04 AM
New guidelines from a leading medical advisory body in China are incorporating 'miracle cure' medications such as Ozempic into weight loss treatments, potentially changing the lives of millions and boosting sales for drugmakers. Bryan Williams from the British Heart Foundation expressed optimism about Ozempic's potential to help with extreme weight loss and other conditions. Ozempic, originally developed to treat diabetes, has shown promise in aiding weight loss and reducing risks of cardiovascular issues. Recent studies indicate that semaglutide, the active ingredient in Ozempic, is effective in reducing the progression from prediabetes to type 2 diabetes. Despite the enthusiasm, experts urge caution, noting the need for long-term studies to fully understand the drug's effects. Additionally, new research has found no increased risk of mental health issues among users of semaglutide for weight loss.
View original story
Similar markets
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Significant reduction • 25%
Moderate reduction • 25%
No significant change • 25%
Increase in events • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
No new data released • 25%
Reduction below 20% • 25%
Reduction between 20% and 30% • 25%
Reduction above 30% • 25%
Heart Disease • 25%
Stroke • 25%
Chronic Kidney Disease • 25%
Other • 25%
Increased Coverage • 25%
Decreased Coverage • 25%
No Change • 25%
Other Health Risks Highlighted • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
